Recent Therapeutic Advances in Parkinson’s Disease

Dear Colleagues,

Parkinson's disease (PD) is a progressive neurological disorder associated with a number of motor, cognitive and psychomotor symptoms. Medication is primarily used as the current treatment to modify neurotransmitters and treat symptoms. The gold standard for PD treatment is dopamine replacement therapy with levodopa. Nevertheless, the treatment for PD is aimed at improving symptoms and cannot slow the progression of the disease. New laboratory medicine research, translation medicinal research, and preclinical studies are providing new directions for treating this disease. The understanding of the mechanism of PD and the development of treatments that influence the fundamental pathology of the condition are advancing.

This Special Issue aims to assemble high-quality original articles and reviews on the current treatments and recent therapeutic developments in PD and related disorders.

Dr. Chieh-Sen Chuang
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Biomedicines is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

• Parkinson's disease
• disease-modifying therapy
• continuous dopaminergic stimulation
• non-dopaminergic drugs
• deep brain stimulation
• drug repurposing
• immunotherapies
• gene therapies